OncoMatch/Clinical Trials/NCT07089940
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Is NCT07089940 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Myc Inhibitor OMO-103 for locally advanced pancreatic ductal adenocarcinoma.
Treatment: Myc Inhibitor OMO-103 — This early phase I trial studies the biological activity of OMO-103 in patients with pancreatic ductal adenocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). OMO-103 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial may help researchers determine how exposure to OMO-103 changes pancreatic tumor cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: MYC inhibitor
Prior treatment with a MYC inhibitor
Cannot have received: anti-cancer therapy
Exception: hormone replacement therapy is acceptable; palliative radiotherapy is acceptable
Concomitant use of other anti-cancer therapy otherwise not permitted in this protocol, including: chemotherapy, immunotherapy, hormonal therapy (hormone replacement therapy is acceptable), radiotherapy (except for palliative), biological therapy, or other novel agent
Cannot have received: anti-cancer therapy
Prior anti-cancer therapy within 2 weeks prior to study enrollment
Lab requirements
Blood counts
Hemoglobin ≥ 7.5 g/dL; ANC ≥ 1.0 x 10^9/L (> 1500 per mm^3); Platelet count ≥ 75 x 10^9/L (> 100,000 per mm^3)
Kidney function
Calculated creatinine clearance > 50 mL/min/1.73m^2 (per Cockcroft-Gault equation)
Liver function
AST/ALT ≤ 3 x ULN, or ≤ 5 x ULN in presence of liver metastases
Hemoglobin ≥ 7.5 g/dL; ANC ≥ 1.0 x 10^9/L (> 1500 per mm^3); Platelet count ≥ 75 x 10^9/L (> 100,000 per mm^3); Calculated creatinine clearance > 50 mL/min/1.73m^2 (per Cockcroft-Gault equation); AST/ALT ≤ 3 x ULN, or ≤ 5 x ULN in presence of liver metastases
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- OHSU Knight Cancer Institute · Portland, Oregon
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify